eFFECTOR Therapeutics, Inc. announced a clinical collaboration with Jennifer Caswell-Jin, M.D., Assistant Professor of Medicine at Stanford Medicine, who will serve as principal investigator in an investigator-initiated trial evaluating zotatifin in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2) breast cancer in a pre-operative setting. This trial will bring to the clinic the science of integrative subgroups of breast cancer, building on work done by Christina Curtis, Ph.D., Professor of Medicine, Genetics, and Biomedical Data Science, and Director of Artificial Intelligence and Cancer Genomics at Stanford Medicine. The primary objective of the study is to assess change in tumor proliferative status, as measured by Ki67 staining, from baseline to 14 days after preoperative treatment with either regimen.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.79 USD | -4.28% | -10.50% | -84.68% |
May. 09 | EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 04 | Health Care Down on Retreat From Risk -- Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-84.68% | 8.42M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.45% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- EFTR Stock
- News eFFECTOR Therapeutics, Inc.
- EFFECTOR Therapeutics, Inc. to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer